What could your deciding factor be?

Find a treatment specifically created for von Willebrand disease (VWD) bleeding episodes1

As an adult living with VWD, you may share a bleeding disorder with others, but you also may have your own Deciding Factor—something that drives you to ask your healthcare provider about finding a treatment that's right for you.

The only VWD factor treatment that's manufactured without human blood or plasma.2,3

Can be used with or without recombinant FVIII as directed.1

Created specifically to
treat VWD

VONVENDI® is used to treat bleeds in adults with von Willebrand disease (VWD), an inherited bleeding disorder that makes it difficult to form blood clots.1 VONVENDI is the first and only recombinant treatment for VWD, meaning it's made without using human blood.2,3 Recombinant products have virtually no risk of being exposed to disease that can be spread through contamination by infected human blood.2

VONVENDI is also the first and only recombinant treatment for VWD that's approved for three uses including:

  • Routine prophylaxis in appropriate adult patients with severe type 3 VWD1
  • On-demand to manage active bleeds1
  • Perioperative to help prevent bleeding episodes during or after surgery1
Learn about VONVENDI

Living with VWD

VWD can change your life, and no one knows that experience better than the people who face it every day.

Learn about VWD
Use as prophylaxis

In certain adult patients with severe Type 3 VWD, VONVENDI is approved to reduce the frequency of bleeding episodes.1

Learn more
Try for free

You may be eligible to try VONVENDI for free with our FREEDOM OF CHOICE ™ program.

Learn more


  1. VONVENDI Prescribing Information
  2. Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
  3. Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment